Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Summary as of May 17, 2018

May 17, 2018 - By Andrea Bass

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 0.53, from 2017Q3’s 1.73. The ratio dropped due to Aerie Pharmaceuticals, Inc. positioning: 23 sold and 48 reduced. 21 funds amassed positions and 64 increased positions. Investors holded 34.42 million in 2017Q3 but now own 34.86 million shares or 1.29% more.
Atlantic Trust Limited Liability Co has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 500 shs. Prelude Capital Management Ltd Liability Com accumulated 0.15% or 31,967 shs. Sei Invs invested in 0% or 4,140 shs. The Germany-based Deutsche Savings Bank Ag has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Senzar Asset Mngmt holds 4.25% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 278,400 shs. Granite Point Management L P reported 46,000 shs. Federated Investors Pa has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Macquarie Ltd accumulated 0.01% or 52,620 shs. Schwab Charles Inv Management Inc owns 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 164,605 shs. Alyeska Inv Group Inc Limited Partnership owns 136,127 shs or 0.07% of their US capital. First Personal Fincl Svcs invested in 543 shs. Amer Int Grp reported 22,322 shs. 126,829 are owned by Rhenman & Ptnrs Asset Mngmt. Wells Fargo And Com Mn reported 22,991 shs. Essex Investment Mgmt Limited Liability Corporation invested in 77,072 shs.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:AERI)’s analyst reports since December 18, 2017 according to StockzIntelligence Inc. On Wednesday, January 24 Canaccord Genuity maintained the shares of AERI in report with “Buy” rating. In Thursday, March 29 report Mizuho maintained it with “Buy” rating and $8700 target. On Monday, December 18 Cantor Fitzgerald maintained the shares of AERI in report with “Buy” rating. In Tuesday, January 2 report Stifel Nicolaus maintained the stock with “Buy” rating. On Tuesday, May 8 the firm earned “Buy” rating by Cantor Fitzgerald. On Thursday, March 1 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by H.C. Wainwright. On Wednesday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, May 9 the rating was maintained by Mizuho with “Buy”. In Friday, February 16 report H.C. Wainwright reinitiated it with “Buy” rating and $78 target. On Wednesday, May 9 the firm earned “Buy” rating by H.C. Wainwright. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

AERI hit $51.15 during the last trading session after $0.05 change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has also 226,563 shares volume. The stock outperformed the S&P 500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.02 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news brought out briefly go to: Benzinga.com, Globenewswire.com, Businesswire.com, Benzinga.com or Gurufocus.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” brought out on May 08, 2018, “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …” on May 03, 2018, “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” with a publish date: April 26, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” and the last “9 Stocks Ron Baron Continues to Buy” with publication date: May 17, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.